Transcat, Inc. (NASDAQ:TRNS) Shares Bought by Calamos Advisors LLC

Calamos Advisors LLC increased its stake in Transcat, Inc. (NASDAQ:TRNS) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,281 shares of the scientific and technical instruments company’s stock after purchasing an additional 634 shares during the quarter. Calamos Advisors LLC owned about 0.11% of Transcat worth $1,015,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of America Corp DE lifted its stake in shares of Transcat by 184.9% in the 1st quarter. Bank of America Corp DE now owns 83,687 shares of the scientific and technical instruments company’s stock worth $6,790,000 after acquiring an additional 54,314 shares during the period. Comerica Bank acquired a new stake in Transcat in the third quarter worth approximately $5,221,000. Vanguard Group Inc. boosted its stake in Transcat by 13.3% during the 3rd quarter. Vanguard Group Inc. now owns 425,378 shares of the scientific and technical instruments company’s stock valued at $41,674,000 after purchasing an additional 49,828 shares in the last quarter. Fred Alger Management LLC increased its position in shares of Transcat by 6.1% during the 1st quarter. Fred Alger Management LLC now owns 727,225 shares of the scientific and technical instruments company’s stock valued at $65,007,000 after purchasing an additional 41,563 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Transcat by 196.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 59,482 shares of the scientific and technical instruments company’s stock worth $5,827,000 after buying an additional 39,432 shares in the last quarter. Institutional investors own 98.34% of the company’s stock.

Transcat Trading Up 2.7 %

Shares of TRNS opened at $108.04 on Monday. The business’s 50-day moving average price is $108.50 and its 200 day moving average price is $102.11. The company has a current ratio of 3.37, a quick ratio of 2.81 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $953.99 million, a P/E ratio of 83.11 and a beta of 0.59. Transcat, Inc. has a 1-year low of $74.89 and a 1-year high of $115.41.

Transcat (NASDAQ:TRNS) last announced its earnings results on Monday, January 29th. The scientific and technical instruments company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.35 by $0.03. Transcat had a net margin of 4.16% and a return on equity of 9.32%. The company had revenue of $65.17 million during the quarter, compared to analysts’ expectations of $63.36 million. Analysts expect that Transcat, Inc. will post 1.34 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Charles P. Hadeed sold 700 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $113.00, for a total value of $79,100.00. Following the completion of the sale, the director now owns 22,678 shares in the company, valued at $2,562,614. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Lee D. Rudow sold 2,373 shares of the firm’s stock in a transaction that occurred on Saturday, March 30th. The shares were sold at an average price of $111.43, for a total transaction of $264,423.39. Following the completion of the sale, the chief executive officer now directly owns 103,688 shares in the company, valued at $11,553,953.84. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Charles P. Hadeed sold 700 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $113.00, for a total transaction of $79,100.00. Following the completion of the transaction, the director now owns 22,678 shares in the company, valued at approximately $2,562,614. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,073 shares of company stock valued at $900,023. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on TRNS. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 target price (up from $120.00) on shares of Transcat in a report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $124.00 target price on shares of Transcat in a report on Tuesday, April 16th. Finally, TheStreet upgraded shares of Transcat from a “c+” rating to a “b” rating in a research report on Wednesday, January 31st.

Transcat Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.